{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-085982","form_type":"8-K","ticker":"ZBIO","cik":"0001953926","company_name":"Zenas BioPharma, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.685745+00:00","generated_at":"2026-05-17T08:59:46.541115+00:00","sec_items":["1.01","2.01","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zenas BioPharma secures up to $300M from Royalty Pharma for obexelimab royalty","bullets":["Royalty Pharma pays $75M upfront; additional $75M upon INDIGO trial success, $75M on FDA approval for IgG4-RD, $75M on FDA approval for SLE.","Royalty Pharma receives 5.5% royalty on worldwide net sales of obexelimab and certain other payments.","Zenas expects cash to fund operations through Q1 2027; topline Phase 3 INDIGO results expected year-end 2025.","Obexelimab is in Phase 3 for IgG4-RD, Phase 2 for RMS and SLE; potential U.S. launch in H1 2027 if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-085982","json":"https://secwatch.observer/filing/0001104659-25-085982.json","markdown":"https://secwatch.observer/filing/0001104659-25-085982.md","text":"https://secwatch.observer/filing/0001104659-25-085982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925085982/0001104659-25-085982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925085982/tm2524961d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:59:46.541115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}